Exosomes secreted from cancer-associated fibroblasts elicit anti-pyrimidine drug resistance through modulation of its transporter in malignant lymphoma
Open accessThe DOI matches its Crossref record; 34 of the 35 references it cites were found in a registry or an index.
Abstract
The tumor microenvironment is deeply involved in the process of tumor growth and development. In this study, we focused on cancer-associated fibroblasts (CAFs) and their derived exosomes on the lymphoma microenvironment to uncover their clinical significance. CAFs were established from primary lymphoma samples, and exosomes secreted from CAFs were obtained by standard procedures. We then investigated the roles of CAFs and their derived exosomes in the survival and drug resistance of lymphoma cells. CAFs supported the survival of lymphoma cells through increased glycolysis, and the extent differed among CAFs. Exosomes were identified as a major component of the extracellular vesicles from CAFs, and they also supported the survival of lymphoma cells. The suppression of RAB27B, which is involved in the secretion of exosomes, using a specific siRNA resulted in reduced exosome secretion and decreased survival of lymphoma cells. Moreover, anti-pyrimidine drug resistance was induced in the presence of exosomes through the suppression of the pyrimidine transporter, equilibrative nucleoside transporter 2 (ENT2), and the suppression of ENT2 was significant in in vivo experiments and clinical samples. RNA sequencing analysis of miRNAs in exosomes identified miR-4717-5p as one of the most abundant miRNAs in the exosome, which suppressed the expression of ENT2 and induced anti-pyrimidine drug resistance in vitro. Our results suggest that exosomes including miR-4717-5p secreted from CAFs play a pivotal role in the lymphoma microenvironment, indicating that they are a promising therapeutic target.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







![Fig. 8 CAFs affect ENT2 expression and anti-pyrimidine susceptibility in xenograft models. A ENT2 expression in HGBL-NOS cells with or without CAFs subcutaneously transplanted in the flanks of the xenograft model. Pathological specimens of tumors from HGBL-NOS cells (upper), HGBL-NOS cells with CAF1 (center), and HGBL-NOS cells with CAF2 (lower) were stained with hematoxylin and eosin (left) and ENT2 (right). B Schema of in vivo experiments. After tumors formed up to 300 mm3 from HGBL-NOS cells or HGBL-NOS cells with CAF1, mice were treated with gemcitabine (n = 3 for HGBL-NOS cells with CAF1, n = 4 for HGBL-NOS cells) for 3 days. Untreated mice (n = 4 for HGBL-NOS cells with CAF1, n = 4 for HGBL-NOS cells) were set as controls. Tumor volumes were measured, and mice treated with gemcitabine were killed and analyzed on day 12. Mice untreated were killed on day 9 when the tumor size exceeded 2500 mm3. C Tumor volumes from HGBL-NOS cells with CAF1 (red line) and HGBL-NOS cells (blue line) treated with gemcitabine, and untreated HGBL-NOS cells with CAF1 (orange line) and HGBL-NOS cells (green line). Each point is the mean taken from 3 or 4 mice with error bars indicating standard error. Asterisk indicates p value: **0.01 > p ≥ 0.001. D Photographs of mice injected with HGBL-NOS cells with CAF1 (left) and HGBL-NOS cells (right) after gemcitabine treatment on day 12. E Pathological specimens of 3 tumors [(a) to (c)] from HGBL-NOS cells with CAF1 on day 12. Specimens stained with H&E (left, low power field [LPF]; center right, high power field [HPF]) and TUNEL (center left; LPF, right; HPF) are shown. F Pathological specimens of 4 tumors [(a) to (d)] from HGBL-NOS cells on day 12. Specimens of each tumor stained with H&E (left, LPF; center right, HPF) and TUNEL (center left, LPF; right; HPF) are shown. Original magnifications: LPF ×40 and HPF ×400.](https://figures.cochat.ai/paper-figures/6d979e5266fe494087e4566235e1bdf2/exosomes-secreted-from-cancer-associated-fibroblasts-elicit-anti-pyrimidine-drug-figure-8.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thus, exosomes are produced by almost all cell types [21,22,23,24,25,26].”
From The Impact of Neurotoxin Proteins Trafficked by Primary Cilia and Extracellular Vesicles in Neurodegenerative Diseases (2025) · cites this paper as [25]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Skog, J., Würdinger, T., van Rijn, S., Meijer, D. H., Gainche, L., Curry, W. T., Carter, B. S., Krichevsky, A. M., & Breakefield, X. O. (2008) · Nature Cell Biology · doi:10.1038/ncb1800 · Cited by 5,001 · cited 2×
“Although the clinical significance of exosomes secreted from tumor cells has been investigated previously [16, 28, 32], we demonstrated that exosomes secreted from CAFs were involved in the survival of lymphoma cells and in drug resistance to anti-pyrimidine drugs in the present study.”
BackgroundResultRevised Response Criteria for Malignant Lymphoma
Cheson, B. D., Pfistner, B., Juweid, M. E., Gascoyne, R. D., Specht, L., Horning, S. J., Coiffier, B., Fisher, R. I., Hagenbeek, A., Zucca, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2403 · Cited by 4,426
Orimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET
Peinado, H., Alečković, M., Lavotshkin, S., Matei, I., Costa-Silva, B., Moreno-Bueno, G., Hergueta-Redondo, M., Williams, C., García-Santos, G., Ghajar, C. M., et al. (2012) · Nature Medicine · doi:10.1038/nm.2753 · Cited by 3,715 · cited 1×
“Although the clinical significance of exosomes secreted from tumor cells has been investigated previously [16, 28, 32], we demonstrated that exosomes secreted from CAFs were involved in the survival of lymphoma cells and in drug resistance to anti-pyrimidine drugs in the present study.”
BackgroundRab27a and Rab27b control different steps of the exosome secretion pathway
Ostrowski, M., Carmo, N. B., Krumeich, S., Fanget, I., Raposo, G., Savina, A., Moita, C. F., Schauer, K., Hume, A. N., Freitas, R. P., et al. (2010) · Nature Cell Biology · doi:10.1038/ncb2000 · Cited by 2,750 · cited 2×
“We further analyzed the relationship between the exosome amount with the expressions of neutral sphingomyelinase 2 (nSMase2), which is an enzyme that synthesizes ceramide, and RAB27B, which is an exosome secretion-associated protein of the small Rab GTPase family [25, 28].”
BackgroundMethodOutcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
Crump, M., Neelapu, S. S., Farooq, U., Van Den Neste, E., Kuruvilla, J., Westin, J., Link, B. K., Hay, A., Cerhan, J. R., Zhu, L., et al. (2017) · Blood · doi:10.1182/blood-2017-03-769620 · Cited by 1,703 · cited 1×
“However, about half of patients with malignant lymphoma show intractable disease; in particular, the prognoses of patients with insufficient responses to initial treatment are very poor [6].”
BackgroundCoiffier, B., Thieblemont, C., Van Den Neste, E., Lepeu, G., Plantier, I., Castaigne, S., Lefort, S., Marit, G., Macro, M., Sebban, C., et al. (2010) · Blood · doi:10.1182/blood-2010-03-276246 · Cited by 1,540
Dave, S. S., Wright, G., Tan, B., Rosenwald, A., Gascoyne, R. D., Chan, W. C., Fisher, R. I., Braziel, R. M., Rimsza, L. M., Grogan, T. M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041869 · Cited by 1,418 · cited 7×
“In the TME, components of EVs are associated with various biological processes.”
BackgroundInfluentialExosomes Mediate Stromal Mobilization of Autocrine Wnt-PCP Signaling in Breast Cancer Cell Migration
Luga, V., Zhang, L., Viloria-Petit, A. M., Ogunjimi, A. A., Inanlou, M. R., Chiu, E., Buchanan, M., Hosein, A. N., Basik, M., & Wrana, J. L. (2012) · Cell · doi:10.1016/j.cell.2012.11.024 · Cited by 1,311 · cited 1×
“In breast cancer, fibroblast-derived exosomes promote metastasis by activating Wnt-PCP signaling in tumor cells [19].”
Background
Cited by
Emerging role of exosomes in cancer progression and tumor microenvironment remodeling
Paskeh, M. D. A., Entezari, M., Mirzaei, S., Zabolian, A., Saleki, H., Naghdi, M. J., Sabet, S., Khoshbakht, M. A., Hashemi, M., Hushmandi, K., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01305-4 · Cited by 563
Metabolic reprogramming of cancer-associated fibroblasts and its effect on cancer cell reprogramming
Li, Z., Sun, C., & Qin, Z. (2021) · Theranostics · doi:10.7150/thno.62378 · Cited by 390
“investigated the roles of CAFs and their exosomes in the survival and drug resistance of lymphoma cells [63].”
BackgroundApoptosis Deregulation and the Development of Cancer Multi-Drug Resistance
Neophytou, C. M., Trougakos, I. P., Erin, N., & Papageorgis, P. (2021) · Cancers · doi:10.3390/cancers13174363 · Cited by 371
Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1/PD-L1 immunotherapy for solid cancers
Pei, L., Liu, Y., Liu, L., Gao, S., Gao, X., Feng, Y., Sun, Z., Zhang, Y., & Wang, C. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01731-z · Cited by 257
“efficacy Exosomes are the main components of extracellular vesicles, with a diameter of 30–150 nm, which contain complex RNA components and proteins [104].”
BackgroundPeng, Z., Tong, Z., Ren, Z., Ye, M., & Hu, K. (2023) · Molecular Medicine · doi:10.1186/s10020-023-00665-y · Cited by 91
Metadata
- Authors
- Kunou, S., Shimada, K., Takai, M., Sakamoto, A., Aoki, T., Hikita, T., Kagaya, Y., Iwamoto, E., Sanada, M., Shimada, S., Hayakawa, F., Oneyama, C., & Kiyoi, H.
- Affiliations
- Nagoya University (JP)
- Aichi Cancer Center (JP)
- National Hospital Organization (JP)
- Nagoya University Hospital (JP)
- Corresponding author
- Shimada, Kazuyuki
- ORCID
- Venue
- Oncogene
- Published
- 2021-05-16
- Volume
- 40
- Issue
- 23
- Pages
- 3989-4003
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- PMC
- PMC8195743
- OpenAlex
- W3160330004
- Cited by
- 62
- References
- 35
- Citations by year
- 2026: 7 · 2025: 19 · 2024: 12 · 2023: 11 · 2022: 8 · 2021: 5
- FWCI
- 2.83
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Oncogene (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Institutional Repositories DataBase (IRDB) (submittedVersion)
- Funders
- MEXT | Japan Society for the Promotion of Science (17K09922, 20K08751)
- MEXT | Japan Science and Technology Agency
- Japan Agency for Medical Research and Development
- Takeda Science Foundation
- Hori Sciences and Arts Foundation
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- cancer-associated fibroblasts, exosomes, lymphoma, ENT2, Rab27b, exosome secretion, tumor microenvironment, lymphoma cell survival, glycolysis, extracellular vesicles, microRNA
- MeSH terms
- Cancer-Associated Fibroblasts, Gemcitabine, Animals, Antimetabolites, Antineoplastic, Cytarabine, Deoxycytidine, Humans, Lymphoma, Male, Mice, SCID, Mice, Inbred NOD, Drug Resistance, Neoplasm, Xenograft Model Antitumor Assays, Equilibrative-Nucleoside Transporter 2, MicroRNAs, Cell Line, Tumor, Cell Proliferation, Mice, Exosomes, Tumor Microenvironment, Primary Cell Culture
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Exosomes secreted from cancer-associated fibroblasts elicit anti-pyrimidine drug resistance through modulation of its transporter in malignant lymphoma. https://app.cochat.ai/papers/10.1038/s41388-021-01829-y
- The paper
- Kunou, S., Shimada, K., Takai, M., Sakamoto, A., Aoki, T., Hikita, T., Kagaya, Y., Iwamoto, E., Sanada, M., Shimada, S., Hayakawa, F., Oneyama, C., & Kiyoi, H. (2021). Exosomes secreted from cancer-associated fibroblasts elicit anti-pyrimidine drug resistance through modulation of its transporter in malignant lymphoma. Oncogene. https://doi.org/10.1038/s41388-021-01829-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.